Search Results
Oct 28, 2025, 09:00 ET MOTORMIA reveals most popular brands among U.S. auto enthusiasts in 2025
5 EBC Breaks
More news about: MOTORMIA
Oct 27, 2025, 16:15 ET Simpson Manufacturing Co., Inc. Announces 2025 Third Quarter Financial Results and Updates 2025 Guidance
accessed through https://viavid.webcasts.com/starthere.jsp?ei=1735146&tp_key=4ec4ebc4d2 or a link on the Company's website at https://ir.simpsonmfg.com.
More news about: Simpson Manufacturing Co., Inc.
Oct 20, 2025, 08:00 ET HOLDCO ASSET MANAGEMENT ISSUES PUBLIC PRESENTATION TO THE BOARD OF DIRECTORS OF EASTERN BANKSHARES, INC.
https://holdcoam.co/EBC In the presentation, HoldCo disclosed that it owns common stock of Eastern Bankshares, Inc. (NASDAQ Global Select Market: EBC) and consequently has an economic interest in the price
More news about: HoldCo Asset Management
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
adults with HR+, HER2-, node-positive EBC at high risk of recurrence. The study enrolled patients across more than 600 sites in 38 countries and is the only adjuvant study designed to investigate a CDK4/6 inhibitor specifically in a node-positive, high-risk EBC population. To be enrolled in Cohort 1
More news about: Eli Lilly and Company
Oct 13, 2025, 09:00 ET Simpson Manufacturing Co., Inc. to Announce Third Quarter 2025 Financial Results on Monday, October 27th
https://viavid.webcasts.com/starthere.jsp?ei=1735146&tp_key=4ec4ebc4d2
More news about: Simpson Manufacturing Co., Inc.
Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting
interstitial lung disease (ILD) or pneumonitis can occur in patients treated with Verzenio and other CDK4/6 inhibitors. In Verzenio-treated patients in EBC (monarchE), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In Verzenio-treated
More news about: Eli Lilly and Company
Sep 30, 2025, 09:00 ET FDA dos EUA aprova Inluriyo (imlunestrant) para adultos com câncer de mama avançado ou metastático ER+, HER2- e com mutação ESR1
O Inluriyo também está sendo estudado no ensaio EMBER-4 de Fase 3 em andamento no cenário adjuvante para pessoas com câncer de mama precoce (EBC) ER+, HER2– com risco aumentado de recorrência, que está recrutando aproximadamente 8.000 pacientes em todo o mundo.
More news about: Eli Lilly do Brasil
Sep 25, 2025, 14:01 ET U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
future." Inluriyo is also being studied in the ongoing Phase 3 EMBER-4 trial in the adjuvant setting for people with ER+, HER2– early breast cancer (EBC) at increased risk of recurrence, which is enrolling approximately 8,000 patients worldwide. Inluriyo is expected to be available in the
More news about: Eli Lilly and Company
Sep 15, 2025, 23:37 ET EBC 파이낸셜 그룹, 글로벌 어워드 연속 수상… 신뢰와 혁신으로 금융거래 새 기준 제시
있다. 핀테크 혁신이 금융산업 전반을 흔드는 가운데, EBC는 안정성과 투명성을 핵심 가치로 내세우며 글로벌 시장에서 영향력을 확대해 왔다. 지난 3년간 EBC 파이낸셜 그룹은 "가장 투명한 브로커"부터 "글로벌 베스트 거래 플랫폼"에 이르기까지 수십 건의 상을 연이어 수상했다. 이를 통해 글로벌 선도 금융사의 위상을 다시 한번 입증했다. EBC 파이낸셜 그룹은 변동성이 커지는 금융시장에서 우수한 거래 환경이 곧 투자자 보호와 경험 향상의 핵심이라는 점을 강조한다. 회사는 '글로벌 최고 브로커'라는 타이틀에 걸맞게
More news about: EBC Financial Group